(NASDAQ: ORKA) Oruka Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.66%.
Oruka Therapeutics's earnings in 2026 is -$105,433,000.On average, 14 Wall Street analysts forecast ORKA's earnings for 2026 to be -$118,966,864, with the lowest ORKA earnings forecast at -$153,423,805, and the highest ORKA earnings forecast at -$99,878,065. On average, 13 Wall Street analysts forecast ORKA's earnings for 2027 to be -$138,387,599, with the lowest ORKA earnings forecast at -$179,156,279, and the highest ORKA earnings forecast at -$89,474,100.
In 2028, ORKA is forecast to generate -$168,024,037 in earnings, with the lowest earnings forecast at -$232,077,782 and the highest earnings forecast at -$96,236,677.